Get the Stockscreener App
60.28
1.23%
0.73
After Hours:
61.00
0.72
+1.19%
Cg Oncology Inc stock is traded at $60.28, with a volume of 530.60K.
It is up +1.23% in the last 24 hours and down -9.94% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$59.55
Open:
$59.9
24h Volume:
530.60K
Relative Volume:
0.47
Market Cap:
$5.32B
Revenue:
$5.07M
Net Income/Loss:
$-186.75M
P/E Ratio:
-25.73
EPS:
-2.3424
Net Cash Flow:
$-160.43M
1W Performance:
+6.37%
1M Performance:
-9.94%
6M Performance:
+59.26%
1Y Performance:
+136.76%
1-Day Range:
$58.96
$60.61
1-Week Range:
$54.60
$61.27
52-Week Range:
$23.65
$75.50
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 409-3700
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare CGON vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
60.28 | 5.25B | 5.07M | -186.75M | -160.43M | -2.3424 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CG Oncology touts cretostimogene data, BLA progress in bladder cancer push - MSN
Midday Stock Roundup: CG Oncology gains - Orange County Business Journal
CG Oncology, Inc. (CGON) upgraded to buy: Here's what you should know - MSN
CG Oncology, Inc. (CGON) reports Q1 loss, tops revenue estimates - MSN
CG Oncology (CGON) Valuation Check As Cretostimogene Nears Phase 3 Data And Planned Regulatory Filing - Sahm
TD Asset Management Inc Grows Stock Position in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. $CGON Shares Purchased by Clearbridge Investments LLC - MarketBeat
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead - MarketBeat
CGON: Pivotal NMIBC trial results and regulatory filings position cretostimogene for first approval - TradingView
CenterBook Partners LP Sells 326,116 Shares of CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ: CGON) investors back directors, EY and pay plan - Stock Titan
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push - MarketBeat
CGON Technical Analysis & Stock Price Forecast - Intellectia AI
CGON Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CG Oncology (CGON) director receives 9,354 stock options at $56.09 strike - Stock Titan
CG Oncology (NASDAQ: CGON) director receives 9,354 stock options at $56.09 exercise price - Stock Titan
[Form 4] CG Oncology, Inc. Insider Trading Activity - Stock Titan
CG Oncology (NASDAQ: CGON) director receives 9,354-share stock option grant - Stock Titan
CG Oncology (NASDAQ: CGON) director receives grant of 9,354 stock options at $56.09 - Stock Titan
CG Oncology set to report earnings as bladder cancer data looms - Investing.com
Wall Street analysts think CG Oncology, Inc. (CGON) could surge 29.78%: Read this before placing a bet - MSN
Will Upcoming Catalysts Reignite CGON's Momentum? - RTTNews
[144] CG Oncology, Inc. SEC Filing - Stock Titan
CGON: Cretostimogene shows durable efficacy and safety in NMIBC, with pivotal data and launch prep ongoing - TradingView
CGON: Cretostimogene shows durable efficacy in NMIBC, with BLA progress and commercial launch preparations advancing - TradingView
Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Did CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative? - Yahoo Finance
CGON stock up 60.8% in six months: Here's what you need to know - MSN
CG Oncology to Present at Upcoming Investor Conferences in June - The Manila Times
CG Oncology CEO joins June fireside chats at Jefferies and Goldman Sachs - Stock Titan
BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $87 - Moomoo
CG Oncology Chief Operating Officer Ambaw Bellete to Depart - Moomoo
CG Oncology, Inc. Announces Chief Commercial Officer Search and Executive Changes in May 2026 8-K Filing - Minichart
CG Oncology (CGON) President & COO to depart as Arthur Kuan named President - Stock Titan
CGON Stock Chart | CG ONCOLOGY INC (NASDAQ:CGON) - ChartMill
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference - MarketBeat
CGON: Cretostimogene advances toward broad NMIBC use with strong data, scalable manufacturing, and launch prep - TradingView
TimesSquare Capital Management LLC Decreases Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Wolfe Research initiates coverage of CG Oncology (CGON) with peer perform recommendation - MSN
CG Oncology stock initiated at Peerperform by Wolfe Research - Investing.com Nigeria
Public immunotherapy drugmaker, Lyda Hill's investment firm grow at Pegasus Park - The Business Journals
CG Oncology Initiated at Peer Perform by Wolfe Research - Moomoo
CGON Initiated Coverage by Wolfe Research -- Rating: Peer Perfor - GuruFocus
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
SUO-CTC and CG Oncology Announce Award Recipients of the - GlobeNewswire
CG Oncology stock initiated at Peerperform by Wolfe Research By Investing.com - Investing.com South Africa
Wolfe Research Initiates CG Oncology(CGON.US) With Hold Rating - Moomoo
CGON Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cg Oncology Inc Stock (CGON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| POST LEONARD E | Director |
Jun 04 '26 |
Sale |
54.50 |
1,000 |
54,500 |
0 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):